 Pfizer Inc. PFE, 0.26 and German partner BioNTech SE BNTX, 5.53 said Thursday early data from a Phase 23 clinical trial of their omicron BA.4BA.5-adapated bivalent booster showed positive results in treating individuals aged 18 and older. The data collected 7 days after administering a 30-ug booster dose showed a substantial increase in neutralizing antibodies. 